Hah! What?! I don't mean to be critical, but Keith, the public looks to you and others within your organization to convince the FDA to decide in your favor. Well, you know, maybe the ancillary work products like clinical trials and documented WRD will do the trick. You know, one could interpret this tweet as a sign of weakness. With the upcoming, May 29th, (slam dunk) meeting, this is not the kind of public shout-out I would expect to get from a BIEL executive. I don't know, maybe I'm reading too much in to this!
Oh, well! Go! BIEL!
GLTA!!!